17 June 2008
Human Leukocyte Antigen (HLA) B-27 and older age are associated with augmented cyclosporine blood bioavailability in renal allograft recipients: An attempt toward individualization of immunosuppression
Eghlim Nemati, Saeed Taheri, Vahid Pourfarziani, Behzad EinollahiAnn Transplant 2008; 13(2): 32-36 :: ID: 858104
Abstract
Background: Therapeutic drug monitoring of cyclosporine (CsA) blood values in renal transplant recipients is of extreme importance; hence, finding contributing factors in this issue is relevant. In this study, we aimed to evaluate potential associations of some characteristics of the recipients including their human leukocyte antigen haplotypes with their drug bioavailability.
Material/Methods: 616 patients who had a valid HLA typing result concomitant with other demographic data in our local data registry were consecutively selected. We extracted their HLA typing, age, gender, weight, cause of renal failure, first measured CsA trough level (C0) and concomitantly measured creatinine, CsA administered dosage, time duration from transplantation, routine laboratory test results, panel reactive antibodies percentage, and immunosuppression type. Bivariate and multivariate linear regressions were employed to evaluate associations of these factors with blood C0 values.
Results: 64.5% of patients were male. Mean age at transplantation was 40.7±15.8. Mean first measured C0 was 271±178 ng/ml. Analysis showed that the only factors which had independent association with C0 were age at transplantation, dose/weight ratio and HLA-B27.
Conclusions: genetic factors as well as age of patients are two founded factors in this study which are recommended to be considered in monitoring drug administration in organ transplant recipients.
Keywords: therapeutic drug monitoring, Cyclosporine, human leukocyte antigen (HLA), Transplantation, HLA-B27
436 2
In Press
10 Nov 2023 : Original article
Effects of Preservation of Donor Liver Gastroduodenal Artery on Post-Transplant Biliary Complications in 18...Ann Transplant In Press; DOI:
07 Nov 2023 : Original article
Allogeneic Hematopoietic Stem Cell Transplantation Can Improve Prognosis of Extramedullary Infiltration Pos...Ann Transplant In Press; DOI:
06 Nov 2023 : Original article
Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Pref...Ann Transplant In Press; DOI:
06 Nov 2023 : Original article
Short-Term Monitoring of Graft Regeneration in Partial Liver Transplantation RecipientsAnn Transplant In Press; DOI:
Most Viewed Current Articles
24 Aug 2021 : Review article
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860